Prana looks at Huntington’s
Tuesday, 02 December, 2008
Melbourne company Prana Biotechnology is investigating the potential of its lead compound, PBT2, in Huntington’s disease.
PBT2, a metal-protein-attenuating compound (MPAC), is in Phase IIb clinical trials for Alzheimer’s disease.
The compound reduces the toxic metal-protein interaction seen in both neurological diseases and has a neuroprotective effect.
Chairman of Prana’s R&D advisory board, Professor Jeffery Cummings, told the company’s AGM that a report commissioned from an independent clinical research group recommended that Prana proceed to clinical trials.
Prana is in confidential talks with several pharma companies with a view to licensing PBT2, the company said.
Overuse of inhalers can increase heart attack risk
Overuse of reliever inhalers is associated with higher risks of developing and dying from...
Unhealthy Western diet could accelerate cognitive decline
An unhealthy Western-style diet is associated with a faster cognitive decline in people with a...
Cancer drug enters clinical trials based on a false mechanism
A cancer drug currently being tested in patients appears to have entered clinical trials based on...
